Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN

Overview

Journal Clin J Am Soc Nephrol

Specialty Nephrology

Date 2023 Aug 24

PMID 37615951

Authors

Marie Sophie Meuleman

Paula Vieira-Martins

Carine El Sissy

Vincent Audard

Veronique Baudouin

Dominique Bertrand

Frank Bridoux

Ferielle Louillet

Claire Dossier

Vincent Esnault

Noemie Jourde-Chiche

Alexandre Karras

Marie-Pascale Morin

Francois Provot

Philippe Remy

David Ribes

Caroline Rousset-Rouviere

Aude Servais

Eric Thervet

Leila Tricot

Mohamad Zaidan

Alain Wynckel

Julien Zuber

Moglie le Quintrec

Veronique Fremeaux-Bacchi

Sophie Chauvet

Affiliations

Soon will be listed here.

Abstract

Background: C3 glomerulopathy and idiopathic immunoglobulin-mediated membranoproliferative GN (Ig-MPGN) are rare complement-mediated kidney diseases. Inherited forms of C3 glomerulopathy/Ig-MPGN are rarely described.

Methods: Three hundred ninety-eight patients with C3 glomerulopathy ( n =296) or Ig-MPGN ( n =102) from a national registry were screened for three complement genes: factor H ( CFH ), factor I ( CFI ), and C3 . Patients with rare variant (minor allele frequency <0.1%) were included. Epidemiologic, clinical, and immunologic data at diagnosis and kidney outcomes of patients were retrospectively collected.

Results: Fifty-three different rare variants, including 30 (57%), 13 (24%), and ten (19%) in CFH , CFI , and C3 variants, were identified in 66/398 (17%) patients. Thirty-eight (72%) variants were classified as pathogenic, including 20/30 (66%) and 11/13 (84%) variants in CFH and CFI , respectively, impairing synthesis of factor H or factor I regulators. Fifteen of 53 (27%) variants were of unknown significance. At diagnosis, 69% of patients were adult (median age of 31 years). With the exception of biologic stigma of thrombotic microangiopathy, which was more frequent in patients with CFI variants (5/14 [36%] versus 1/37 [3%] and 0% in the CFH group and C3 group, respectively, P < 0.001), the clinical and histologic features were similar among the three variants groups. The kidney outcome was poor regardless of the age at onset and treatment received. Sixty-five percent (43/66) of patients with rare variant reach kidney failure after a median delay of 41 (19-104) months, compared with 28% (55/195) after a median delay of 34 (12-143) months in the nonvariant group. Among 36 patients who received a kidney transplant, 2-year recurrence was frequent, occurring in 39% (12/31), without difference between variant groups, and led to graft failure in three cases.

Conclusions: In our cohort, 17% of C3 glomerulopathy/Ig-MPGN cases were associated with rare variants in the CFH , CFI , or C3 genes. In most cases, a quantitative deficiency in factor H or factor I was identified. The presence of a rare variant was associated with poor kidney survival.

Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_08_CJN0000000000000252.mp3.

Citing Articles

C3 glomerulopathy is highly prevalent in French Polynesia.

Candela N, Benichou N, Lefebvre M, Gueguen L, Vieira-Martins P, El Sissy C J Transl Autoimmun. 2024; 9:100254.

PMID: 39554253 PMC: 11565528. DOI: 10.1016/j.jtauto.2024.100254.

Functional Characterization of Anti-C3bBb Autoantibodies and C3 Glomerulopathy Phenotype.

Roquigny J, Meuleman M, El Sissy C, Cailliez M, Servais A, Roussey G J Am Soc Nephrol. 2024; 36(2):264-273.

PMID: 39325562 PMC: 11801764. DOI: 10.1681/ASN.0000000000000499.

Proof of concept of a new plasma complement Factor H from waste plasma fraction.

Mori F, Pascali G, Berra S, Lazzarotti A, Panetta D, Rocchiccioli S Front Immunol. 2024; 15:1334151.

PMID: 38919628 PMC: 11197005. DOI: 10.3389/fimmu.2024.1334151.

Podocyte-targeted therapies - progress and future directions.

Meliambro K, He J, Campbell K Nat Rev Nephrol. 2024; 20(10):643-658.

PMID: 38724717 DOI: 10.1038/s41581-024-00843-z.

References

Chauvet S, Roumenina L, Bruneau S, Marinozzi M, Rybkine T, Schramm E . A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. J Am Soc Nephrol. 2015; 27(6):1665-77. PMC: 4884110. DOI: 10.1681/ASN.2015040348. View

Wong E, Hallam T, Brocklebank V, Walsh P, Smith-Jackson K, Shuttleworth V . Functional Characterization of Rare Genetic Variants in the N-Terminus of Complement Factor H in aHUS, C3G, and AMD. Front Immunol. 2021; 11:602284. PMC: 7840601. DOI: 10.3389/fimmu.2020.602284. View

Fritsche L, Igl W, Cooke Bailey J, Grassmann F, Sengupta S, Bragg-Gresham J . A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2015; 48(2):134-43. PMC: 4745342. DOI: 10.1038/ng.3448. View

de Jong S, Volokhina E, de Breuk A, Nilsson S, de Jong E, van der Kar N . Effect of rare coding variants in the CFI gene on Factor I expression levels. Hum Mol Genet. 2020; 29(14):2313-2324. PMC: 7424754. DOI: 10.1093/hmg/ddaa114. View

Kavanagh D, Richards A, Noris M, Hauhart R, Liszewski M, Karpman D . Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol. 2007; 45(1):95-105. DOI: 10.1016/j.molimm.2007.05.004. View

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

Bomback A, Santoriello D, Avasare R, Regunathan-Shenk R, Canetta P, Ahn W . C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int. 2018; 93(4):977-985. DOI: 10.1016/j.kint.2017.10.022. View

Servais A, Noel L, Roumenina L, le Quintrec M, Ngo S, Dragon-Durey M . Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012; 82(4):454-64. DOI: 10.1038/ki.2012.63. View

Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F . Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol. 2019; 30(12):2449-2463. PMC: 6900783. DOI: 10.1681/ASN.2019040331. View

10.

Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey M, Ngo S . Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013; 8(4):554-62. PMC: 3613948. DOI: 10.2215/CJN.04760512. View

11.

Chauvet S, Hauer J, Petitprez F, Rabant M, Vieira Martins P, Baudouin V . Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy. Kidney Int. 2022; 102(4):904-916. PMC: 10588728. DOI: 10.1016/j.kint.2022.05.027. View

12.

Lomax-Browne H, Medjeral-Thomas N, Barbour S, Gisby J, Han H, Bomback A . Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis. Clin J Am Soc Nephrol. 2022; 17(7):994-1007. PMC: 9269630. DOI: 10.2215/CJN.16801221. View

13.

Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E . Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016; 71:131-142. DOI: 10.1016/j.molimm.2016.01.010. View

14.

Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc A, Ville S . Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2020; 137(18):2438-2449. DOI: 10.1182/blood.2020009280. View

15.

Caravaca-Fontan F, Diaz-Encarnacion M, Lucientes L, Cavero T, Cabello V, Ariceta G . Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. Clin J Am Soc Nephrol. 2020; 15(9):1287-1298. PMC: 7480558. DOI: 10.2215/CJN.15241219. View

16.

Dragon-Durey M, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G . Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol. 2004; 15(3):787-95. DOI: 10.1097/01.asn.0000115702.28859.a7. View

17.

Fakhouri F, Fremeaux-Bacchi V . Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol. 2021; 17(8):543-553. DOI: 10.1038/s41581-021-00424-4. View

18.

Hallam T, Marchbank K, Harris C, Osmond C, Shuttleworth V, Griffiths H . Rare Genetic Variants in Complement Factor I Lead to Low FI Plasma Levels Resulting in Increased Risk of Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2020; 61(6):18. PMC: 7415286. DOI: 10.1167/iovs.61.6.18. View

19.

Figueres M, Fremeaux-Bacchi V, Rabant M, Galmiche L, Marinozzi M, Grunfeld J . Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up. Hum Pathol. 2014; 45(11):2326-33. DOI: 10.1016/j.humpath.2014.07.021. View

20.

Pickering M, DAgati V, Nester C, Smith R, Haas M, Appel G . C3 glomerulopathy: consensus report. Kidney Int. 2013; 84(6):1079-89. PMC: 3842953. DOI: 10.1038/ki.2013.377. View